Skip to main content
Springer logoLink to Springer
. 2021 Jan 18;44(8):1679–1688. doi: 10.1007/s40618-020-01475-3

Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern Italy

L Dal Maso 1,, C Panato 1, A De Paoli 2, V Mattioli 1, D Serraino 1, R Elisei 3, G Zoppini 4, C Gobitti 5, E Borsatti 6, E Di Felice 7, F Falcini 8,9, S Ferretti 10, S Francisci 11, P Giorgi Rossi 12, S Guzzinati 2, G Mazzoleni 13, D Pierannunzio 11, S Piffer 14, S Vaccarella 15, M Vicentini 12, M Zorzi 2, S Franceschi 1, U Fedeli 2,; for the DEPTH Working Group
PMCID: PMC8285305  PMID: 33460012

Abstract

Purpose

Evidence of an increased diagnostic pressure on thyroid has emerged over the past decades. This study aimed to provide estimates of a wide spectrum of surveillance indicators for thyroid dysfunctions and diseases in Italy.

Methods

A population-based study was conducted in North-eastern Italy, including 11.7 million residents (20% of the total Italian population). Prescriptions for TSH testing, neck ultrasound or thyroid fine needle aspiration (FNA), surgical procedures, and drugs for hypo- or hyperthyroidism were extracted from regional health databases. Proportions and rates of selected examinations were calculated from 2010 to 2017, overall and by sex, calendar years, age, and region.

Results

Between 2010 and 2017 in North-eastern Italy, 24.5% of women and 9.8% of men received at least one TSH test yearly. In 2017, 7.1% of women and 1.5% of men were prescribed drugs for thyroid dysfunction, 94.6% of whom for hypothyroidism. Neck ultrasound examinations were performed yearly in 6.9% of women and 4.6% of men, with a nearly two-fold variation between areas. Thyroid FNA and thyroidectomies were three-fold more frequent in women (394 and 85 per 100,000) than in men (128 and 29 per 100,000) with a marked variation between areas. Both procedures decreased consistently after 2013.

Conclusions

The results of this population-based study describe recent variations over time and between surrounding areas of indicators of ‘diagnostic pressure’ on thyroid in North-eastern Italy. These results emphasize the need to harmonize practices and to reduce some procedures (e.g., neck ultrasound and total thyroidectomies) in certain areas.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-020-01475-3.

Keywords: Thyroid stimulation hormones (TSH), Neck ultrasound, Fine needle aspiration, Thyroidectomies, Italy

Introduction

Thyroid diseases can be broadly summarized into thyroid dysfunctions (hypothyroidism, hyperthyroidism) and structural diseases (goiter, benign nodules, and cancer). An increased frequency of thyroid diseases has been observed over the past three decades [14].

National and international guidelines and recommendations about the management of thyroid diseases are available [57], but an abuse of testing and diagnostic procedures may lead to wasting of resources, overdiagnosis, and inappropriate treatment [8]. In addition, still open issues concern whether healthy adults can benefit from screening for thyroid diseases, including targeted screening for thyroid dysfunction in any circumstance, including pregnancy [4] and low-radiation exposures [9]. Indeed, the assessment of the thyroid function has become common practice, in particular thyroid function testing through TSH (i.e., the most sensitive marker of thyroid status) that is increasingly included among routine tests for metabolic status or in the presence of a broad range of medical conditions [10, 11]. Concurrently, a massive increase in the neck ultrasound to explore the thyroid gland or other abnormalities of the neck has been reported in many regions of the world [12, 13], and intensity of medical surveillance has been shown to be a major determinant of the large, although heterogeneous, rise in thyroid cancer incidence over the past three decades [8, 1322]. In particular, a very frequent detection of asymptomatic tumors, which may have never caused symptoms or harm, emerged. In addition, an increased search for cancers (incidental microcarcinomas) in patients undergoing surgery for benign thyroid diseases has been observed [12, 2325].

Given the high and increasing thyroid cancer incidence reported in Italy [26], with progressively increasing geographic variation [27], and paucity of population-based studies describing the changes over time of ‘diagnostic pressure’ on thyroid [12, 22, 24, 2831], this study aimed to provide population-based estimates of the frequency and trends of a wide spectrum of medical surveillance indicators for thyroid dysfunction and disease in North-eastern Italy. We explored the variations of thyroid function testing, chronic treatments, neck ultrasound, thyroid fine needle aspiration (FNA), frequency and type of thyroid surgery by sex, over time, and between areas.

Materials and methods

This population-based study was conducted to identify the frequency of thyroid examinations in North-eastern Italy, three administrative regions—Veneto, Emilia-Romagna, and Friuli Venezia Giulia—and two autonomous provinces—Trentino and Alto Adige (Table 1), for a total of 11.7 million residents in 2017 (20% of the total Italian population, 5.7 million men and 6.0 million women). Well comparable and comprehensive regional health system databases are active in this part of Italy, including exhaustive information on medical prescriptions and procedures since the 1990s, and regional population-based cancer registries [26]. The following databases collected by regional health authorities were examined: outpatient services databases; hospital discharge databases; and drug prescriptions databases (Online Appendix 1). Prescriptions for TSH testing (ICD9-CM code 90.42.1) [32], neck ultrasound examinations (ICD9-CM codes 88.71.4, 88.71.5, 88.73.5); and thyroid FNA (i.e., FNA biopsy or FNA cytology, ICD9-CM codes 06.01, 06.01.1, 06.11.1, 06.11.2) were retrieved from outpatient services databases in each year from 2010 to 2017 by area, sex, and age.

Table 1.

Regions included in the study, population, and proportion of people who underwent selected thyroid examinations at least once in any year. North-eastern Italy, 2010–2017

graphic file with name 40618_2020_1475_Figa_HTML.gif Population Drugs for hypo-hyperthyroidisma TSH Neck ultrasound Thyroid fine needle aspiration Thyroidectomies Thyroid cancerb
Million Mean Per 100 Per 100,000
Agec
2017 2017 2010–2017d 2010–2017d 2010–2017d 2010–2017d 2010–2012d
Men Women Men Women Men Women Men Women Men Women Men Women
Region
 Total 11.65 45.5 1.5 7.1 9.8 24.5 4.6 6.9 128 394 29 85 10 21
 Veneto 4.91 45.1 1.1 5.5 8.7 22.6 4.3 6.1 106 327 28 86 8 21
 Emilia-Romagna (ER) 4.46 45.9 1.8 8.5 11.2 27.0 5.2 8.2 172 536 35 95 15 24
 Friuli Venezia Giulia (FVG) 1.22 47.1 1.5 7.9 8.1 21.5 3.7 5.4 107 354 21 65 7 18
 Trentino 0.54 44.2 1.6 8.2 10.8 31.0 5.6 8.2 71 205 16 49 6 18
 Alto Adige/South Tyrol (AA) 0.53 42.5 1.5 6.7 10.6 22.3 2.9 4.3 70 78 27 77 5 11

aAt least two drug prescriptions in 2017

bAdapted from Dal Maso et al. [26], age 0–84 years

chttp://dati.istat.it/Index.aspx?DataSetCode=DCIS_INDDEMOG1#

dAverage number of people undergoing each test or procedure at least once per year

Surgical procedures, including partial (ICD9-CM codes 06.2, 06.3x, 06.51) [33] and total (ICD9-CM codes 06.4, 06.50, 06.52) thyroidectomies for any indication were extracted from hospital discharge databases for each year between 2010 and 2017 by area, sex, and age. The number of FNA was also extracted from Hospital Discharge databases. For each individual only one procedure of TSH testing, neck ultrasound, thyroid FNA, and thyroidectomy per year was counted.

In order to characterize the prevalence of people living with “chronic” thyroid dysfunction, including hyperthyroidism or hypothyroidism (for all reasons, including thyroidectomies), individuals with at least two prescriptions for thyroid (ATC code H03AA) [34] and anti-thyroid (code H03BB) preparations were identified in 2017 from the drug prescriptions databases.

On account of the descriptive purpose of the present research and the demographic similarities of the examined regions, we computed only crude proportions and rates of selected examinations from 2010 to 2017, overall and by sex, calendar years, age, and region.

Results

In 2017, 7.1% of women and 1.5% of men living in North-eastern Italy were prescribed, at least twice, drugs for hypothyroidism or hyperthyroidism (Table 1). Drugs use increased linearly with age until 65–74 years in women (13.1%) and 75 years or older in men (4.0%) (Fig. 1). The vast majority (94.6%) of these prescriptions were thyroid hormones (mainly levotiroxine) for hypothyroidism, the remaining 5.4% were thyroid inhibitors (mainly thiamazole, also known as methimazole) used to treat hyperthyroidism. The highest proportions of drugs for hypo/hyperthyroidism emerged in Emilia Romagna (8.5% in women and 1.8% in men) (Table 1).

Fig. 1.

Fig. 1

People to whom drugs for hypothyroidism or hyperthyroidism were prescribed at least twice in 2017, by sex and age group. North-eastern Italy

Between 2010 and 2017, 24.5% of women and 9.8% of men received at least one prescription for TSH testing each year (Table 1). No substantial variations over time were found in either men or women (Fig. 2). The frequency of TSH testing reached > 20% of women aged 25 years or older, with values exceeding 35% at 65–74 years. A more gradual increase with age was found for men, among whom TSH testing was performed > 10% yearly after 65 years and > 20% in those aged 75–84 years. The only remarkable geographical variation was found in Trentino where, among women aged 25–34, nearly 40% were tested for TSH yearly, i.e., approximately two-fold more than in other areas (Online Appendix 2).

Fig. 2.

Fig. 2

Rates of TSH, neck ultrasound, thyroid fine needle aspiration, and thyroidectomy (any type) by calendar year, sex, and age group. North-eastern Italy, 2010–2017

Neck ultrasound examinations were performed at least once per year in 6.9% of women and 4.6% of men (Table 1). The peak of neck ultrasounds occurred at ages 65–74 years in women (16%) and 75–84 years in men (15%) (Fig. 2). The proportion of individuals undergoing neck ultrasound slightly increased between 2010 and 2017 (i.e., from 6.6 to 7.0% in women and from 4.3 to 4.8% in men) with a nearly two-fold higher frequency in Emilia-Romagna and Trentino than in Alto Adige (Table 1 and Online Appendix 2).

Thyroid FNA were threefold more frequent in women than men (394 and 128 per 100,000, respectively) with a seven-fold variation between the highest (i.e., Emilia-Romagna) and lowest (Alto Adige) frequency areas in women. Corresponding variation in men was 2.5-fold (Table 1). Women-to-men ratio was consistent in different age groups with a peak at 65–74 years in both sexes (767 in women and 327 per 100,000 in men) (Fig. 2). In women, a consistent decrease of FNA emerged throughout the study period, from 429 in 2010 to 334 per 100,000 in 2017, with a decrease > 6% per year after 2014. In men, 134 per 100,000 FNA were reported yearly in 2013–2014, but they declined to 121 FNA per 100,000 in 2017.

The annual number of thyroidectomies was approximately three-fold higher in women (85 per 100,000) than in men (29 per 100,000) (Table 1), with a tendency to decline after 2014. Thyroidectomies increased with age, reaching a plateau at 45–74 years in women and at 55–74 years in men (Fig. 2). Total thyroidectomies were 71 per 100,000 women in 2010, 73 per 100,000 in 2013 and 2014, decreasing to 61 per 100,000 women in 2017 (Fig. 3). Partial thyroidectomies were 16 per 100,000 women in 2010 and 19 per 100,000 women in 2017. Men also showed a decrease in the frequency of total thyroidectomies from 2013 to 2017 (23 and 20 per 100,000 men, respectively) and an increase of partial thyroidectomies from 2012 to 2017 (6.4 and 7.8 per 100,000 men). Notably, the frequency of thyroidectomies was also two-fold higher in Emilia Romagna than in Trentino in both sexes (Online Appendix 2). In women, total thyroidectomies represented more than 75% of all thyroidectomies throughout the examined period, with one partial thyroidectomy every 4.3 total thyroidectomies in 2010, increasing to 4.8 in 2013 (83%), but declining to one partial thyroidectomy every 3.3 total thyroidectomies in 2017 (77%). In men, 3.3 total thyroidectomies were performed for every partial thyroidectomy in 2011 (77%) and 2.5 in 2017 (71%).

Fig. 3.

Fig. 3

Rates of total and partial thyroidectomies by calendar year, sex, and age group. North-eastern Italy, 2010–2017

The relative frequency of selected procedures was also shown as the ratio of neck ultrasound to FNA and FNA to thyroidectomy (Fig. 4). In women, one FNA was performed every 15.4 neck ultrasound examinations in 2010, increasing to 21.0 in 2017. In men this ratio was two-fold higher, one FNA was performed every 34 neck ultrasound examinations in 2010 and every 40 in 2017. The FNA to thyroidectomy ratios were similar in men and women (i.e., approximately one thyroidectomy every 4.5 FNA), showing negligible variations over time.

Fig. 4.

Fig. 4

Number of neck ultrasound for every thyroid fine needle aspiration (FNA) and number of thyroid FNA for every thyroidectomy (any type) by calendar year and sex. North-eastern Italy, 2010–2017

Discussion

This study provides the first population-based evaluation of annual rates of thyroid function testing, neck ultrasound, FNA, and thyroidectomies in 2010–2017 in North-eastern Italy, an area with nearly 12 million inhabitants, 20% of the Italian population.

We found that a large proportion of individuals living in North-eastern Italy underwent thyroid function testing. The percentages of individuals who were tested for TSH at least once per year (25% in women and 10% in men) were consistent with those reported in other countries, such as France [14], Canada [35], UK [36], and Australia [10]. Particularly high frequency of TSH testing was reported in women in Trentino (31% overall and 33% since age 25–34 years, Online Appendix 2), providing confirmation of local variability of thyroid function testing shown elsewhere [36].

Our indirect estimates of the proportion of individuals who received treatments for hypo- (4.1%) or hyperthyroidism (0.23%) in 2017 (4.3% overall) were similar to those obtained elsewhere using a population-based design. In the United Kingdom, the prevalence of treated hypothyroidism increased from 2.3% in 2005 to 3.5% in 2014 [37]. A survey in Spain showed that 4.2% of the population was treated for hypothyroidism and 0.8% for hyperthyroidism [38], while in the USA thyroid hormones (i.e., levotyroxine) were prescribed to 6.4% of adults in 2011–2012 [39]. The association between thyroid dysfunctions and thyroid cancers has received increasing attention [40], but a causal link with thyroid cancer has been firmly established only for nodules [41], while it is still controversial for goiter, hypo- or hyperthyroidism [42].

The frequency of annual neck ultrasound examinations we found (7% in women and 5% in men) was even higher than that reported in other studies, i.e., 2–3% in France [14], 1.5% in USA [13], and 1% in Canada [43]. Of note, thyroid nodules are often incidental findings as neck ultrasound is performed for the examination of carotid arteries (i.e., diseases unrelated to thyroid) and there was a two-fold higher frequency of thyroid FNA per neck ultrasound in women than men.

Our estimates of annual FNA (128 per 100,000 men and 394 per 100,000 women) are also higher than those reported in the only comparable population-based study in France (i.e., approximately 200 FNA per 100,000 population, men and women combined) [14]. Interestingly, FNA is the examination that shows the largest variation (i.e., > two-fold) across study areas. The decrease of FNA in the study period was more marked in the study area with the highest yearly rates (i.e., Emilia Romagna, Online Appendix 2). Information on overall reduction of FNA with substantially unchanged rates of neck ultrasound may suggest of a more stringent selection of nodules that needed further examination during the last study years.

The number of thyroidectomies in North-eastern Italy for any indication between 2010 and 2017 (29 per 100,000 men and 85 per 100,000 women per year, 58 per 100,000 overall) was similar to the results reported in France [14] and the United States [25], until 2012 and 2014. Notably, in our study the frequency of total thyroidectomies has shown a downward trend since 2015, probably as a consequence of the reduction of FNA since 2015 and according to the most recent guidelines recommending that only > 1 cm nodules should be evaluated, since they have a greater potential to be clinically significant cancers [5]. In addition, after 2015 we observed a more conservative surgery approach with low but increasing rates of partial thyroidectomies. These findings could mirror, to some extent, the cultural trend induced by the worldwide steep increase of papillary microcarcinoma, in favor of a less aggressive diagnostic attitude towards small thyroid tumors. This trend culminated in the contents of 2015 ATA guidelines [5], which include a recommendation against FNA for < 10 mm diameter thyroid nodules, even when suspicious on ultrasound basis. The ATA guidelines were preceded by meeting sessions, editorials as well as review articles which anticipated this less aggressive vision [5].

Italy is one of the countries where the burden of thyroid cancer incidence and overdiagnosis is among the largest worldwide [19, 26] and the areas in the present study include the highest and lowest thyroid cancer incidence rates in Italy [26]. In North-eastern Italy, persons living after a thyroid cancer diagnosis were 0.2% of the overall population in 2010 [44], most of them cured [45] but still needing lifelong treatments. Age-adjusted incidence rates in 2010–2012 in South Tyrol were 11 per 100,000 women and 5 per 100,000 men, while nearly threefold higher rates were found in Emilia Romagna (i.e., 24 per 100,000 women and 15 per 100,000 men) [26]. Among the indicators of diagnostic pressure evaluated in the study, the strongest correlation with thyroid cancer incidence was found for FNA rates (Spearman correlation > 0.7 in men and women). In women, a strong correlation also emerged for neck ultrasound (Spearman 0.76), consistently with results in South Korea, where screening is the most important driver of the epidemic of thyroid cancer, particularly among females [16]. The frequency of ultrasonography for thyroid screening reached coverage > 15% in some South Korean regions and is 3- to 4-fold higher than the frequency of neck ultrasound recorded in our study. No favourable effect of screening on thyroid cancer mortality emerged [16, 20].

Strengths of the presents study include the population-based design, the inclusion of a substantial part of Italian population, and the availability of data until 2017. Study limitations are the lack of linkage individuals for different tests performed, and of information on the determinants of examinations and their appropriateness according to current guidelines. In addition, we could not assess the outcomes of examinations performed.

Our results are not meant to recommend ideal testing frequency for TSH, neck ultrasound, or thyroid FNA in our, as well as in other populations [8]. Several comorbidities other than known or suspected thyroid diseases may have prompted TSH testing (e.g., type 2 diabetes or hypertension) [11] and neck ultrasound examination (e.g., carotid stenosis). Recently, patterns of TSH testing, the most commonly prescribed thyroid examination by clinicians, have been explored in Canada [46], showing a relatively high proportion (22%) of TSH testing not conforming to current test-ordering guidelines. Moreover, benign thyroid nodules can be safely followed with less intense protocols than those proposed in the past years [47].

In the paucity of population-based data on the appropriateness of current practice of thyroid clinical impact of test overuse or underuse [11, 48], future studies linking individual number of different thyroid examinations would be of great interest, particularly in specific population subgroups (women < 25 years, the elderly population). These studies would further increase the knowledge on the pathways to the diagnosis of thyroid cancer and other thyroid disorders, to differentiate clinically relevant diseases from those with no impact on mortality [19, 49]. In addition, they would contribute to evaluate adherence to evolving guidelines [5, 7, 50] and they should be used to reduce unnecessary medicalization of patients [51] and unnecessary costs for the healthcare system [23, 52, 53].

Conclusion

Variations in the frequency of thyroid examination across otherwise rather similar Italian regions suggest the need for a reappraisal of the indications for the detection and management of thyroid disorders. There is certainly room for a reduction of FNA examinations in some areas. According to growing evidence suggesting the feasibility of more conservative surgical approaches [54], indications to total thyroidectomy may be reconsidered. Most of all, the evidence of a first impact of recent recommendations [7, 55, 56] on thyroid diagnosis and treatments in real-life clinical practice stresses the need of further dissemination efforts, sharing, and implementation of emerging evidence-based guidelines.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

The authors thank Mrs. Luigina Mei for editorial assistance. Members of the Diagnostic Examinations and Pathway of THyroid diseases (DEPTH) working group: Francesco Avossa (Epidemiological Department, Azienda Zero, Padua); Rossana De Palma (Emilia Romagna Region); Rosa Vattiato (Romagna Cancer Registry); Andrea Polverino (Trento Province); Fabio Vittadello (South Tyrol Cancer Registry); Federica Toffolutti, Giuseppe Fanetti (CRO, Aviano).

Funding

This work was supported by the Italian Association for Cancer Research (AIRC) (Grant no. 16921) and by the Italian Ministry of Health (Ricerca Corrente, RCR-2020-23670066, Alliance Against Cancer: Overdiagnosis, overtreatment, and outcome in cancer patients, WP 7). The funding sources had no involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

Data availability

Dataset supporting our findings is available, upon reasonable request, by the corresponding author.

Compliance with ethical standards

Conflict of interest

The authors have declared no competing interests.

Ethics approval and consent to participate

The Italian legislation identifies regional health authorities as collectors of personal data for surveillance purposes without explicit individual consent. The approval of a research ethic committee is not required, since this study is a descriptive analysis of anonymous aggregate data without any direct or indirect intervention on patients (Decreto del Presidente del Consiglio dei Ministri, 3/3/2017, Identificazione dei sistemi di sorveglianza e dei registri di mortalità, di tumori e di altre patologie, 17A03142, GU Serie Generale n.109 del 12-05-2017). Available at: http://www.gazzettaufficiale.it/eli/id/2017/05/12/17A03142/sg, last access: 15/07/2020.

Footnotes

The members of the DEPTH Working Group are listed in Acknowledgements.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

L. Dal Maso, Email: epidemiology@cro.it

U. Fedeli, Email: ugo.fedeli@azero.veneto.it

for the DEPTH Working Group:

F. Avossa, R. De Palma, R. Vattiato, A. Polverino, F. Vittadello, F. Toffolutti, and G. Fanetti

References

  • 1.Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94:1853–1878. doi: 10.1210/jc.2008-2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Garmendia Madariaga AG, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99:923–931. doi: 10.1210/jc.2013-2409. [DOI] [PubMed] [Google Scholar]
  • 3.Walsh JP. Managing thyroid disease in general practice. Med J Aust. 2016;205:179–184. doi: 10.5694/mja16.00545. [DOI] [PubMed] [Google Scholar]
  • 4.Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301–316. doi: 10.1038/nrendo.2018.18. [DOI] [PubMed] [Google Scholar]
  • 5.Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, et al. Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update. Endocr Pract. 2016;22:622–639. doi: 10.4158/EP161208.GL. [DOI] [PubMed] [Google Scholar]
  • 7.Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M, et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Investig. 2018;41:849–876. doi: 10.1007/s40618-018-0884-2. [DOI] [PubMed] [Google Scholar]
  • 8.Hall SF, Webber C, Groome PA, Booth CM, Nguyen P, DeWit Y. Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada. Cancer Med. 2019;8:850–859. doi: 10.1002/cam4.1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.IARC Expert Group on Thyroid Health Monitoring after Nuclear Accidents (2018) Thyroid health monitoring after nuclear accidents, vol 46. IARC Technical Publications, Lyon
  • 10.Hong A, Stokes B, Otahal P, Owens D, Burgess JR. Temporal trends in thyroid-stimulating hormone (TSH) and thyroid peroxidase antibody (ATPO) testing across two phases of iodine fortification in Tasmania (1995–2013) Clin Endocrinol (Oxf) 2017;87:386–393. doi: 10.1111/cen.13371. [DOI] [PubMed] [Google Scholar]
  • 11.Werhun A, Hamilton W. Thyroid function testing in primary care: overused and under-evidenced? A study examining which clinical features correspond to an abnormal thyroid function result. Fam Pract. 2015;32:187–191. doi: 10.1093/fampra/cmv010. [DOI] [PubMed] [Google Scholar]
  • 12.Brito JP, Al Nofal A, Montori VM, Hay ID, Morris JC. The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in olmsted county, minnesota during 1935 through 2012. Thyroid. 2015;25:999–1007. doi: 10.1089/thy.2014.0594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Haymart MR, Banerjee M, Reyes-Gastelum D, Caoili E, Norton EC. Thyroid ultrasound and the increase in diagnosis of low-risk thyroid cancer. J Clin Endocrinol Metab. 2019;104:785–792. doi: 10.1210/jc.2018-01933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mathonnet M, Cuerq A, Tresallet C, Thalabard JC, Fery-Lemonnier E, Russ G, et al. What is the care pathway of patients who undergo thyroid surgery in France and its potential pitfalls? A national cohort. BMJ Open. 2017;7:e013589. doi: 10.1136/bmjopen-2016-013589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid. 2015;25:1127–1136. doi: 10.1089/thy.2015.0116. [DOI] [PubMed] [Google Scholar]
  • 16.Ahn HS, Kim HJ, Kim KH, Lee YS, Han SJ, Kim Y, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26:1535–1540. doi: 10.1089/thy.2016.0075. [DOI] [PubMed] [Google Scholar]
  • 17.Lin JS, Bowles EJA, Williams SB, Morrison CC. Screening for thyroid cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2017;317:1888–1903. doi: 10.1001/jama.2017.0562. [DOI] [PubMed] [Google Scholar]
  • 18.Lortet-Tieulent J, Franceschi S, Dal Maso L, Vaccarella S. Thyroid cancer "epidemic" also occurs in low- and middle-income countries. Int J Cancer. 2019;144:2082–2087. doi: 10.1002/ijc.31884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8:468–470. doi: 10.1016/S2213-8587(20)30115-7. [DOI] [PubMed] [Google Scholar]
  • 20.Jun JK, Hwang SY, Hong S, Suh M, Choi KS, Jung KW. Association of screening by thyroid ultrasonography with mortality in thyroid cancer: a case-control study using data from two national surveys. Thyroid. 2020;30:396–400. doi: 10.1089/thy.2019.0460. [DOI] [PubMed] [Google Scholar]
  • 21.Colbeth HL, Genere N, Hall CB, Jaber N, Brito JP, El Kawkgi OM, et al. Evaluation of medical surveillance and incidence of post-September 11, 2001, thyroid cancer in world trade center-exposed firefighters and emergency medical service workers. JAMA Intern Med. 2020;180:888–895. doi: 10.1001/jamainternmed.2020.0950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Sosa JA, Hanna JW, Robinson KA, Lanman RB. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery. 2013;154:1420–1426. doi: 10.1016/j.surg.2013.07.006. [DOI] [PubMed] [Google Scholar]
  • 23.Ho TW, Shaheen AA, Dixon E, Harvey A. Utilization of thyroidectomy for benign disease in the United States: a 15-year population-based study. Am J Surg. 2011;201:570–574. doi: 10.1016/j.amjsurg.2010.12.006. [DOI] [PubMed] [Google Scholar]
  • 24.Pelizzo MR, Rubello D, Bernardi C, Gemo G, Bertazza L, Schievano E, et al. Thyroid surgical practices shaping thyroid cancer incidence in North-Eastern Italy. Biomed Pharmacother. 2014;68:39–43. doi: 10.1016/j.biopha.2013.10.001. [DOI] [PubMed] [Google Scholar]
  • 25.Francis DO, Randolph G, Davies L. Nationwide variation in rates of thyroidectomy among US medicare beneficiaries. JAMA Otolaryngol Head Neck Surg. 2017;143:1122–1125. doi: 10.1001/jamaoto.2017.1746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Dal Maso L, Panato C, Franceschi S, Serraino D, Buzzoni C, Busco S, et al. The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998–2012. Eur J Cancer. 2018;94:6–15. doi: 10.1016/j.ejca.2018.01.083. [DOI] [PubMed] [Google Scholar]
  • 27.Lise M, Franceschi S, Buzzoni C, Zambon P, Falcini F, Crocetti E, et al. Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. Thyroid. 2012;22:27–34. doi: 10.1089/thy.2011.0038. [DOI] [PubMed] [Google Scholar]
  • 28.Busco S, Giorgi Rossi P, Sperduti I, Pezzotti P, Buzzoni C, Pannozzo F. Increased incidence of thyroid cancer in Latina, Italy: a possible role of detection of subclinical disease. Cancer Epidemiol. 2013;37:262–269. doi: 10.1016/j.canep.2013.02.007. [DOI] [PubMed] [Google Scholar]
  • 29.Van den Bruel A, Francart J, Dubois C, Adam M, Vlayen J, De Schutter H, et al. Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. J Clin Endocrinol Metab. 2013;98:4063–4071. doi: 10.1210/jc.2013-1705. [DOI] [PubMed] [Google Scholar]
  • 30.Panato C, Serraino D, De Santis E, Forgiarini O, Angelin T, Bidoli E, et al. Thyroid cancer in Friuli Venezia Giulia, northeastern Italy: incidence, overdiagnosis, and impact of type of surgery on survival. Tumori J. 2019;105:296–303. doi: 10.1177/0300891619839307. [DOI] [PubMed] [Google Scholar]
  • 31.Rahman ST, McLeod DSA, Pandeya N, Neale RE, Bain CJ, Baade P, et al. Understanding pathways to the diagnosis of thyroid cancer: are there ways we can reduce over-diagnosis? Thyroid. 2019;29:341–348. doi: 10.1089/thy.2018.0570. [DOI] [PubMed] [Google Scholar]
  • 32.Ministero della Salute. Il nuovo nomenclatore: DPCM 12 gennaio 2017. http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=1767&area=programmazioneSanitariaLea&menu=vuoto. Accessed 4 Nov 2020
  • 33.Centers for Disease Control and Prevention. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). https://www.cdc.gov/nchs/icd/icd9cm.htm. Published 2016. Accessed 4 Nov 2020
  • 34.WHO Collaborating Centre for Drug Statistics Methodology (2018) ATC classification index with DDDs, 2019. Oslo, Norway
  • 35.Wintemute K, Greiver M, McIsaac W, Del Giudice ME, Sullivan F, Aliarzadeh B, et al. Choosing Wisely Canada campaign associated with less overuse of thyroid testing: retrospective parallel cohort study. Can Fam Phys. 2019;65:e487–e496. [PMC free article] [PubMed] [Google Scholar]
  • 36.Vaidya B, Ukoumunne OC, Shuttleworth J, Bromley A, Lewis A, Hyde C, et al. Variability in thyroid function test requests across general practices in south-west England. Qual Prim Care. 2013;21:143–148. [PubMed] [Google Scholar]
  • 37.Razvi S, Korevaar TIM, Taylor P. Trends, determinants, and associations of treated hypothyroidism in the United Kingdom, 2005–2014. Thyroid. 2019;29:174–182. doi: 10.1089/thy.2018.0251. [DOI] [PubMed] [Google Scholar]
  • 38.Valdés S, Maldonado-Araque C, Lago-Sampedro A, Lillo JA, Garcia-Fuentes E, Perez-Valero V, et al. Population-based national prevalence of thyroid dysfunction in spain and associated factors: diabetes study. Thyroid. 2017;27:156–166. doi: 10.1089/thy.2016.0353. [DOI] [PubMed] [Google Scholar]
  • 39.Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314:1818–1831. doi: 10.1001/jama.2015.13766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Tran TV, Kitahara CM, de Vathaire F, Boutron-Ruault MC, Journy N. Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis. Endocr Relat Cancer. 2020;27:245–259. doi: 10.1530/ERC-19-0417. [DOI] [PubMed] [Google Scholar]
  • 41.Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control. 1999;10:583–595. doi: 10.1023/A:1008907227706. [DOI] [PubMed] [Google Scholar]
  • 42.Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Overvad K, et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst. 2014;106:dju097. doi: 10.1093/jnci/dju097. [DOI] [PubMed] [Google Scholar]
  • 43.Hall SF, Irish J, Groome P, Griffiths R. Access, excess, and overdiagnosis: the case for thyroid cancer. Cancer Med. 2014;3:154–161. doi: 10.1002/cam4.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.AIRTUM Working Group Italian cancer figures, report 2014: prevalence and cure of cancer in Italy. Epidemiol Prev. 2014;38(6 Suppl 1):1–122. [PubMed] [Google Scholar]
  • 45.Dal Maso L, Panato C, Guzzinati S, Serraino D, Francisci S, Botta L, et al. Prognosis of long-term cancer survivors: a population-based estimation. Cancer Med. 2019;8:4497–4507. doi: 10.1002/cam4.2276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Birk-Urovitz E, Del Giudice M, Meaney C, Grewal K. Use of thyroid-stimulating hormone tests for identifying primary hypothyroidism in family medicine patients. Can Fam Phys. 2017;63:e389–e394. [PMC free article] [PubMed] [Google Scholar]
  • 47.Grani G, Lamartina L, Biffoni M, Giacomelli L, Maranghi M, Falcone R, et al. Sonographically estimated risks of malignancy for thyroid nodules computed with five standard classification systems: changes over time and their relation to malignancy. Thyroid. 2018;28:1190–1197. doi: 10.1089/thy.2018.0178. [DOI] [PubMed] [Google Scholar]
  • 48.O'Sullivan JW, Albasri A, Nicholson BD, Perera R, Aronson JK, Roberts N, et al. Overtesting and undertesting in primary care: a systematic review and meta-analysis. BMJ Open. 2018;8:e018557. doi: 10.1136/bmjopen-2017-018557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Journy NMY, Bernier MO, Doody MM, Alexander BH, Linet MS, Kitahara CM. Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. Thyroid. 2017;27:1001–1010. doi: 10.1089/thy.2017.0063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EUTIRADS. Eur Thyroid J. 2017;6:225–2237. doi: 10.1159/000478927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Jensen CB, Saucke MC, Francis DO, Voils CI, Pitt SC. From overdiagnosis to overtreatment of low-risk thyroid cancer: a thematic analysis of attitudes and beliefs of endocrinologists, surgeons, and patients. Thyroid. 2020;30:696–703. doi: 10.1089/thy.2019.0587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, et al. Annual financial impact of well differentiated thyroid cancer care in the United States. Cancer. 2014;120:1345–1352. doi: 10.1002/cncr.28562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Kiel S, Ittermann T, Völzke H, Chenot JF, Angelow A. Frequency of thyroid function tests and examinations in participants of a population-based study. BMC Health Serv Res. 2020;20(1):70. doi: 10.1186/s12913-020-4910-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center. J Clin Endocrinol Metab. 2020;105:dgz113. doi: 10.1210/clinem/dgz113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14:587–595. doi: 10.1016/j.jacr.2017.01.046. [DOI] [PubMed] [Google Scholar]
  • 56.Lamartina L, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP, et al. Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory. Thyroid. 2017;27:1490–1497. doi: 10.1089/thy.2017.0299. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

Dataset supporting our findings is available, upon reasonable request, by the corresponding author.


Articles from Journal of Endocrinological Investigation are provided here courtesy of Springer

RESOURCES